Pfizer moves forward testing a little-kid vaccine at lower doses!
UncategorizedBig news! Yesterday Pfizer-BioNTech announced that they have completed a Phase I trial to determine the best dose for their COVID-19 vaccine in younger kids, and they’re moving on to Phase 2/3 trials which will test effectiveness and safety in children ages 6 months to 11 years. The short version: the Phase 2/3 trial green Read more…